The Stimulatory Effect of Globular Adiponectin on Insulin-Stimulated Glucose Uptake and Fatty Acid Oxidation Is Impaired in Skeletal Muscle From Obese Subjects

Clinton R. Bruce,1 Valerie A. Mertz,1 George J.F. Heigenhauser,2 and David J. Dyck1

Adiponectin is an adipose-derived hormone that plays an important role in regulating insulin sensitivity in rodents. However, little is known regarding the effect of adiponectin on metabolism in human skeletal muscle. Therefore, we examined whether the globular head of adiponectin, gAcrp30, acutely activates fatty acid oxidation and glucose uptake in isolated human skeletal muscle. Furthermore, we aimed to determine whether these effects would differ in muscle from lean versus obese individuals. Treatment with gAcrp30 (2.5 μg/ml) increased fatty acid oxidation in lean muscle (70%, P < 0.0001) and to a lesser extent in obese muscle (30%, P < 0.01). In the absence of insulin, gAcrp30 increased glucose uptake 37% in lean (P < 0.05) and 33% in obese muscle (P < 0.05). Combined exposure of insulin and gAcrp30 demonstrated an additive effect on glucose uptake in lean and obese individuals, but this effect was reduced by 50% in obese muscle (P < 0.05). These metabolic effects were attributable to an increase in AMP-activated protein kinase-α1 (AMPKα1) and AMPKα2 activity. However, in obese muscle the activation of AMPKα2 by gAcrp30 was blunted. This study provides evidence that gAcrp30 plays a role in regulating fatty acid and glucose metabolism in human skeletal muscle. However, the effects are blunted in obesity, indicating the possible development of adiponectin resistance. Diabetes 54:3154–3160, 2005
After an overnight fast (12–18 h), general anesthesia was induced with a short-acting barbiturate and maintained by a fentanyl and rocuronium volatile anesthetic mixture. Venous blood samples were then collected in 5-ml heparinized tubes during anesthesia. Muscle strip preparation was as previously described (14,15), with minor modifications. A biopsy of 3 × 2 × 1 cm from the rectus abdominus muscle was excised perpendicular to the direction of the muscle fibers, clipped at resting length, and placed in oxygenated ice-cold medium to a 20-ml glass scintillation vial containing 1.0 ml of 1 mol/l H2SO4. Liberated 14CO2 was trapped in the benzethonium hydroxide over 80°C, and it was transferred to a clean centrifuge tube. Distilled water (2.0 ml) was added, and samples were shaken for 10 min and centrifuged as before to separate the aqueous and lipophilic phases. Then, 500 μl of the aqueous phase was quantified by liquid scintillation counting to determine the amount of 14C-labeled oxidative intermediates resulting from isotopic fixation. This represented a twofold correction factor for exogenous [1-14C]palmitate oxidation, as previously described (18). The chloroform phase, which contains the total lipids extracted from muscle, was gently evaporated under a stream of N2 and redissolved in 100 μl of 2:1 chloroform-methanol. Small amounts of dipalmitin and tripalmitin (Sigma Chemical, St. Louis, MO) were added to the 2:1 chloroform-methanol to facilitate the identification of lipid bands on the silica gel plates. We spotted 50 μl of each sample on an oven-dried silica gel plate (Fisher Scientific Canada, Mississauga, ON). Silica gel plates were placed in a sealed tank containing solvent (SO4:50 Hoest–isopropyl ether–acetic acid) for 40 min. Plates were then dried, sprayed with dichlorofluorescein dye (0.02% wt/vol in ethanol), and visualized under longwave ultraviolet light. The individual lipid bands were marked on the plate with a scalpel and scraped into vials for liquid scintillation counting.

AMPK activity. AMPKα1 and -α2 activities were examined after the 30-min preincubation (0 min) and after 20 or 60 min of gAcrp30 treatment. Briefly, muscle strips were incubated in medium 199 (5.5 mmol/l glucose) containing 4 mmol/l pyruvate in the absence or presence of recombinant human gAcrp30 (2.5 μg/ml; Peprotech, Ottawa, ON, Canada). The gAcrp30 concentration was varied between 0.25 and 2.5 μg/ml aprotinin, 1 mmol/l benzamidine, and 1 mmol/l phenylmethylsulfonyl fluoride). The homogenates were washed three times in 1% phosphoric acid. Filter papers were dried and placed in organic scintillant for counting.

Citrated synthase and β-hydroxy-acyl-CoA dehydrogenase activity. Citrate synthase and β-hydroxy-acyl-CoA dehydrogenase (HAD) activity was assayed in a portion of muscle (~10 mg) that was rapidly frozen in liquid N2 immediately after excision. Muscle was homogenized in 100 vol/wt of a 100-mmol/l potassium phosphate buffer solution, and citrate synthase activity was assayed spectrophotometrically at 37°C (20). β-HAD activity was assayed spectrophotometrically at 37°C by measuring the disappearance of NADH, using the whole-muscle homogenate as for citrate synthase (21).

Calculations and statistics. All data are the means ± SE. Differences within groups were determined using paired t tests. To examine differences between the lean and obese groups, unpaired t tests were used. Statistical significance was accepted at P < 0.05. Total palmitate uptake by the muscle strips was calculated by summing the incorporation of labeled palmitate into lipid pools plus oxidation.

RESULTS

Subject characteristics are shown in Table 1. Obese individuals had significantly greater body mass (+27%, P < 0.0001) and BMI (+29%, P < 0.0001) compared with lean subjects. Fasting levels of plasma glucose, free fatty acids, and insulin were not significantly different between lean and obese women (P > 0.05). Adiponectin levels were significantly decreased (~65%, P < 0.05) in obese individuals. The activities of citrate synthase and β-HAD were not different between lean and obese subjects (Table 1) and were comparable to the activities of citrate synthase and β-HAD reported in the vastus lateralis (22), which is a more commonly sampled human muscle.

Muscle strip preparation viability. Muscle viability was preserved during incubations based on maintenance of ATP (0 min, 20.7 ± 0.8; 120 min, 19.1 ± 0.8 μmol/g dry wt)
METHODS. Basal rates of total palmitate uptake were also greater in obese subjects (+25%, P < 0.05) (Table 2). Treatment with gAcrp30 increased total palmitate uptake in lean muscle (+38%, P < 0.05) (Table 2). The ratio of palmitate esterification (DAG and TAG) to oxidation was significantly elevated in obese muscle (+34%, P < 0.05), indicating a partitioning of incorporated fatty acid toward storage (Fig. 2E). The presence of gAcrp30 resulted in a significant reduction in the fatty acid esterification-to-oxidation ratio in lean muscle (−28%, P < 0.05) (Fig. 2E) and obese muscle (−23%, P < 0.01) (Fig. 2E), with the absolute change being similar in the lean and obese subjects (Fig. 2F).

Effect of gAcrp30 on AMPK activity. In the absence of gAcrp30, AMPKα1 activity remained stable in both the lean muscle (0.78 ± 0.10, 0.66 ± 0.10, and 0.73 ± 0.12 pmol·mg protein⁻¹·min⁻¹ for 0, 20, and 60 min, respectively) and obese muscle (0.51 ± 0.10, 0.54 ± 0.12, and 0.70 ± 0.15, respectively). After 60 min of exposure to gAcrp30, AMPKα1 activity was elevated in muscle from both groups (Fig. 3A). AMPKα1 activity was lower in muscle from the obese patients at 0 min (P < 0.05) (Fig. 3A) and remained suppressed after 20 min of gAcrp30 treatment (P < 0.05) (Fig. 3A). After 60 min of gAcrp30 treatment, AMPKα1 activity tended to be reduced in the obese muscle (P = 0.06) (Fig. 3A). Basal AMPKα2 activity was not different between groups (Fig. 3B). Throughout the incubation period, AMPKα2 activity was constant in the untreated control strips from both lean (0.31 ± 0.03, 0.28 ± 0.03, and 0.32 ± 0.05 pmol·mg protein⁻¹·min⁻¹ for 0, 20, and 60 min, respectively) and obese (0.30 ± 0.04, 0.33 ± 0.09, and 0.36 ± 0.07, respectively) patients. Treatment with gAcrp30 for 20 min increased AMPKα2 activity in muscle from lean and obese individuals (Fig. 3B), whereas AMPKα2 remained elevated after 60 min of gAcrp30 treatment only in lean muscle (Fig. 3B). However, there was a trend for AMPKα2 activity to be elevated in obese muscle after 60 min of treatment with gAcrp30 (P = 0.06) (Fig. 3B). At that time, AMPKα2 activity was reduced in the obese compared with the lean subjects (P < 0.01) (Fig. 3B).

DISCUSSION

Adiponectin is a recently discovered adipokine that can exert systemic effects on insulin sensitivity and lipid metabolism in rodents (1). Although low levels of adiponectin are associated with obesity and type 2 diabetes (3,4), suggesting an important role for adiponectin in regulating insulin sensitivity, there is little information on the direct effects of adiponectin on skeletal muscle metabolism in humans. Therefore, in this study we used an isolated human skeletal muscle strip preparation to examine the effects of the globular head of adiponectin, gAcrp30, on glucose uptake and fatty acid metabolism. The biological significance of gAcrp30 is unclear. It has previously been reported that ~1% of total circulating adiponectin is in the globular form (5); the fact that the concentration of adiponectin is ~100-fold greater than other cytokines suggests that this fraction may be of biological significance. However, other studies have not detected the presence of gAcrp, indicating that it is the high-molecular weight forms of diacylglycerol (DAG) was not different between lean and obese subjects and was unaffected by gAcrp30 (Fig. 2C). However, fatty acid esterification into triacylglycerol (TAG) was greater in obese subjects (+69%, P < 0.05) (Fig. 2D). Fatty acid esterification into TAG was not reduced in either lean or obese muscle in the presence of gAcrp30. Basal rates of total palmitate uptake were also greater in obese subjects (+25%, P < 0.05) (Table 2). Treatment with gAcrp30 increased total palmitate uptake in lean muscle (+38%, P < 0.05) (Table 2). The ratio of palmitate esterification (DAG and TAG) to oxidation was significantly elevated in obese muscle (+34%, P < 0.05), indicating a partitioning of incorporated fatty acid toward storage (Fig. 2E). The presence of gAcrp30 resulted in a significant reduction in the fatty acid esterification-to-oxidation ratio in lean muscle (−28%, P < 0.05) (Fig. 2E) and obese muscle (−23%, P < 0.01) (Fig. 2E), with the absolute change being similar in the lean and obese subjects (Fig. 2F).
adiponectin that are biologically important (23,24). Nevertheless, the effect of globular adiponectin on muscle metabolism and insulin sensitivity is certainly of therapeutic significance. To our knowledge, this is the first time that gAcrp30 has been shown to increase glucose uptake in human skeletal muscle. Furthermore, we demonstrate that gAcrp30 had an additive effect on insulin-stimulated glucose uptake. We have also confirmed recent findings (12) that gAcrp30 stimulates fatty acid oxidation in human skeletal muscle. Our results suggest that gAcrp30 stimulates glucose uptake and fatty acid oxidation by activating AMPK. Of particular interest is the finding that the effects of gAcrp30 on insulin-stimulated glucose uptake and fatty acid oxidation are blunted in skeletal muscle of obese individuals, which appears to be due to impaired activation of AMPK.

Effect of gAcrp30 on skeletal muscle glucose uptake. Studies in rodents have reported that gAcrp30 increases glucose uptake in skeletal muscle (1,10). However, no studies have examined the effect of gAcrp30 on glucose uptake in human muscle. Therefore, a major finding of the present study was that gAcrp30 increased glucose uptake in the absence of insulin in skeletal muscle from both lean and obese individuals. Importantly, we also demonstrate that gAcrp30 had an additive effect on insulin-stimulated glucose uptake in skeletal muscle from both lean and obese subjects. Similar observations have recently been reported in L6 myotubes. Ceddia et al. (25) found that gAcrp30 increased basal rates of glucose uptake via trans-

**TABLE 2**

<table>
<thead>
<tr>
<th>Uptake (nmol/g wet wt)</th>
<th>−gAcrp30</th>
<th>+gAcrp30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lean</td>
<td>105.5 ± 13.3</td>
<td>145.5 ± 15.7*</td>
</tr>
<tr>
<td>Obese</td>
<td>131.5 ± 7.1†</td>
<td>142.7 ± 10.8</td>
</tr>
</tbody>
</table>

Data are the means ± SE. n = 8–9 per group. *Significantly different from −gAcrp30 (P < 0.05); †significantly different from lean (P < 0.05).
location of GLUT4 to the cell surface. Furthermore, when used in combination with insulin, gAcrp30 exerted an additive effect on glucose uptake and GLUT4 translocation (25). It should be noted that the pharmacological insulin concentration used in the present study was chosen because this is known to maximally stimulate glucose uptake in an incubation model. Thus, it must be acknowledged that the high level of insulin, particularly in the absence of other hormones and peptides normally present in the circulation, makes it impossible to directly extrapolate our findings to the in vivo condition. Taken together, the results of the current study and those of Ceddia et al. (25) suggest that like muscle contraction and 5-aminoimidazole carboxamide riboside (AICAR), gAcrp30 increases glucose uptake via an insulin-independent mechanism, possibly involving AMPK. It is also noteworthy that in the current study, the stimulation of glucose uptake in the presence of gAcrp30 and insulin was actually greater than that which would be predicted by adding the individual responses to these hormones, i.e., a greater than additive effect. This may imply that adiponectin also increases insulin sensitivity in muscle.

A novel finding of the current study was that the additive effect of gAcrp30 and insulin on glucose uptake was blunted in the muscle from obese patients. Recently, it has been proposed that in animal models of obesity and human type 2 diabetes, adiponectin resistance may develop, resulting in a decrease in the adiponectin effects on fatty acid oxidation and AMPK activation (12,13). Interestingly, in muscle from the obese individuals, the increase in basal glucose uptake in response to gAcrp30 was not impaired, despite reduced activation of AMPK compared with lean muscle. Therefore, these results suggest that the reduction in insulin-stimulated glucose uptake in the muscle from obese individuals may be responsible for the impairment in glucose uptake in response to a combination of gAcrp30 and insulin. Surprisingly, the fasting levels of blood glucose and insulin were not different between the lean and obese groups (Table 1), suggesting that whole-body insulin sensitivity was not actually impaired in the obese subjects. However, it should be noted that these measurements were made after a prolonged fast (12–18 h) before surgery, and that a more dynamic test, such as an euglycemic-hyperinsulinemic clamp or an oral glucose tolerance test, may have revealed a difference in insulin sensitivity between the groups.

**Effect of gAcrp30 on skeletal muscle fatty acid metabolism.** The insulin-sensitizing effect of gAcrp30 has been suggested to be mediated by an increase in fatty acid oxidation (1,10), leading to a reduction in muscle lipid content (6). In the current study, we demonstrated that gAcrp30 increases fatty acid oxidation in skeletal muscle from both lean and obese subjects and that this is associated with enhanced insulin sensitivity. However, similar to the effect on insulin-stimulated glucose uptake, the stimulatory effect of gAcrp30 on fatty acid oxidation is blunted in skeletal muscle from obese individuals. This is consistent with the finding of impaired activation of AMPK in muscle from obese subjects. Our data are in agreement with the recent study of Chen et al. (12), who report that gAcrp30 stimulates fatty acid oxidation in cultured human myotubes and that this response is impaired in obese and obese type 2 diabetic myotubes.

Insulin resistance is associated with accumulation of cytosolic lipids within muscle (26). It has been hypothesized that interventions that increase fatty acid oxidation will improve insulin sensitivity by reducing the accumulation of muscle lipids. Indeed, adiponectin treatment has been shown to improve insulin sensitivity by decreasing muscle triglyceride content (6). Therefore, we examined whether gAcrp30 treatment would affect fatty acid esterification into DAG and TAG pools. Interestingly, fatty acid esterification into DAG and TAG was unaffected by gAcrp30 treatment, despite the observed increase fatty acid oxidation. It is possible that our incubation period was too short in duration to see an effect of gAcrp30 on fatty acid esterification into the endogenous lipid pools. Furthermore, the effect of gAcrp30 on fatty acid esterification into the lipid pools may only become evident when in the presence of other hormones that stimulate lipogenesis, such as insulin. However, despite no changes in the esterification of fatty acids into the lipid pools, we were able to detect a significant reduction in the esterification-to-oxidation ratio in both lean and obese muscle, indicating a partitioning of fatty acid toward oxidation rather than storage.

**Effect of gAcrp30 on AMPK activation.** The signaling pathways regulated by adiponectin are just beginning to be characterized. On binding to its receptor, adiponectin receptor-1, gAcrp30 activates AMPK, which appears to mediate the metabolic effects of gAcrp30 (11). Previous studies using cell culture and isolated rodent muscle have shown that AMPK activity is rapidly and transiently activated by gAcrp30 (1,10). However, here we show that AMPKα1 activity is only activated after 60 min of exposure to gAcrp30 in both lean and obese skeletal muscle. In
contrast, AMPKα2 activity is increased after 20 min of incubation with gAcrp30 in muscle from lean and obese individuals. This effect is maintained in muscle from lean subjects after 60 min of gAcrp30, whereas there was a tendency for AMPKα2 to remain elevated at this time point in muscle from obese subjects. Although we do not know the precise mechanisms underlying these differences, it is possible that species differences exist such that a more prolonged AMPK response is observed in human skeletal muscle after acute treatment with gAcrp30.

Interestingly, we found impaired stimulation of AMPKα1 and α2 by gAcrp30 in skeletal muscle of obese subjects. In fact, we found that the basal activity of AMPKα1 is reduced in obese skeletal muscle. The metabolic significance of this reduction in AMPKα1 activity is unknown because currently it appears that the α2 isoform plays a more important role in regulating substrate metabolism (27,28). Indeed, AMPKα2 knockout mice are resistant to AICAR-induced glucose uptake (27) and develop whole-body insulin resistance (28), whereas AMPKα1 knockout mice appear normal (25). In this regard, the reduction in AMPKα2 activity in the obese subjects may explain the impaired metabolic responses to gAcrp30. Furthermore, it has recently been reported that the mRNA expression of adiponectin receptor-1 is reduced in insulin-resistant rodents (13) and humans (29), which may result in decreased activation of AMPK by gAcrp30.

In conclusion, this is the first study to show that gAcrp30 acutely increases glucose uptake in human skeletal muscle. Furthermore, we show an additive effect of gAcrp30 on insulin-stimulated glucose transport in lean and obese skeletal muscle. These effects may be mediated by a shift in fatty acid partitioning toward oxidation and away from storage, which is likely due to activation of AMPK. Importantly, our data also show that the effects of gAcrp30 on insulin-stimulated glucose uptake and fatty acid oxidation are blunted in skeletal muscle from obese subjects because of impaired activation of AMPK. These results suggest that adiponectin resistance develops in obesity.

ACKNOWLEDGMENTS

This study was funded by National Sciences and Engineering Research Council of Canada Discovery and Collaborative Health Research grants (to D.J.D.) and the Canadian Institutes of Health Research (to D.J.D. and G.J.F.H.).

We acknowledge the excellent technical assistance of Brianne Thrush and Angela Smith. We also gratefully acknowledge the invaluable contribution of the surgeons, Drs. Sibley, Loopstra, and Lightheart.


